No Data
No Data
Jinhe Biotech (002688.SZ): Net profit of 45.1432 million yuan in the first quarter increased 22.27% year-on-year
On April 28, Ge Longhui (002688.SZ) released its report for the first quarter of 2024, with operating income of 519 million yuan, down 1.49% year on year; net profit attributable to shareholders of listed companies was 45.1432 million yuan, up 22.27% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.872 million yuan, up 28.56% year on year; basic earnings per share were 0.0578 yuan.
Jinhe Biology (002688.SZ): The veterinary chemical kinomycin can be used to treat diseases such as respiratory, urinary tract, skin and soft tissue infections in livestock and poultry
Gelonghui, April 2 | Jinhe Biology (002688.SZ) said on the investor interactive platform that the company's veterinary chemical, cinnamomycin, can be used to treat diseases such as respiratory, urinary tract, and skin and soft tissue infections in livestock and poultry. It can also improve feed utilization, shorten the fattening period, and increase survival rate. The company currently has 16 vaccine products, including pig vaccines (porcine blue ear, porcine mycoplasma, pig round, pig round ring, pig foot-and-mouth disease, stomach and stomach duality), ruminant vaccine (bovine sheep disease), pet vaccine (rabies vaccine), etc.
A-share pharmaceutical stocks skyrocketed, and Jinhe Biotech rose or stopped
Glonghui March 27 | Jindaway, Shengda Biotech, and Jinhe Biotech went up and down, while Dali Pharmaceutical, Osecon, and Hokuriku Pharmaceutical surged.
Jinhe Biology (002688.SZ): The company's project with an annual output of 1000 tons of doxycycline hydrochloride has now been put into operation
Gelonghui March 14 | Jinhe Biotech (002688.SZ) said on the investor interactive platform that the company's project with an annual output of 1,000 tons of doxycycline hydrochloride has now been put into operation. The treatment of doxycycline hydrochloride complements the prevention of quinomycin, enriches the company's product system, and can provide better solutions for downstream customers.
Jinhe Biotech (002688.SZ): Has cumulatively repurchased 1.62% of the shares
Gelonghui, March 1, 丨 Jinhe Biotech (002688.SZ) announced that as of February 29, 2024, the company had repurchased a total of 12,653,800 shares through a special securities repurchase account, accounting for 1.62% of the company's total share capital. The highest transaction price was 3.27 yuan/share, the minimum transaction price was 2.92 yuan/share, and the total transaction amount was 387.437 million yuan (not including transaction fees).
Jinhe Biotech (002688.SZ) and related personnel received a warning letter from the Inner Mongolia Securities Regulatory Bureau
Jinhe Biotech (002688.SZ) announced that the company received “On Jinhe Biotechnology...” issued by the Inner Mongolia Securities Regulatory Bureau
No Data